Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

• Status: Recruiting
• Trial end date: 2025-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the effect of the timing of surgery on outcome of patients with nonmetastatic osteosarcoma of pelvis and sacrum.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Cisplatin; Doxorubicin; Ifosfamide; Isophosphamide mustard; Liposomal doxorubicin; Methotrexate

Criteria

Inclusion Criteria:

• Age >10 years and <40 years;

• High-grade nonmetastatic osteosarcoma in pelvis or sacrum;

• Diagnosis confirmed histologically and reviewed centrally;

• No evidence of metastatic disease with computed tomography scan of the chest and radionuclide bone scan, or Positron Emission Tomography (PET/CT) within 2 weeks of entry;

• No prior therapy;

• Eastern Cooperative Oncology Group performance status 0-1;

• Life expectancy >3 months;

• Adequate renal, hepatic, and hemopoietic function;

Exclusion Criteria:

• Previously treated by chemotherapy or unplanned surgery in other hospital;

• Have had other kinds of malignant tumors at the same time;

• Uncontrolled complications, such as diabetes mellitus and so on;

• Intravascular tumor thrombus on enhanced CT or magnetic resonance (MR);

• Unresectable disease evaluated by surgeons.